Abstract
Ataxia telangiectasia (AT) is a recessive syndrome, including cerebellar degeneration, immunologic defects and cancer predisposition1,2, attributed to mutations in the recently isolated ATM (ataxia telangiectasia, mutated) gene3. AT is diagnosed in 1/40,000 to 1/100,000 live births, with carriers calculated to comprise ∼1% of the population. Studies of AT families have suggested that female relatives presumed to be carriers have a 5 to 8-fold increased risk for developing breast cancer4,5, raising the possibility that germline ATM mutations may account for ∼5% of all breast cancer cases. The increased risk for breast cancer reported for AT family members has been most evident among younger women, leading to an age-specific relative risk model predicting that 8% of breast cancer in women under age 40 arises in AT carriers, compared with 2% of cases between 40–59 years6. To test this hypothesis, we undertook a germ-line mutational analysis of the ATM gene in a population of women with early onset of breast cancer, using a protein truncation (PTT) assay to detect chain-terminating mutations, which account for 90% of mutations identified in children with AT7–11. We detected a heterozygous ATM mutation in 2/202 (1%) controls, consistent with the frequency of AT carriers predicted from epidemiologic studies. ATM mutations were present in only 2/401 (0.5%) women with early onset of breast cancer (P = 0.6). We conclude that heterozygous ATM mutations do not confer genetic predisposition to early onset of breast cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Shiloh, Y. Ataxia-telangiectasia: closer to unraveling the mystery. Eur. J. Hum. Genet 3, 116–138 (1995).
Morrell, D. Cromartie, E. & Swift, M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77, 89–92 (1986).
Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749–1753 (1995).
Swift, M. Reitnauer, P. Morrell, D. & Chase, C. Breast and other cancers in families with ataxia-telangiectasia. New Engl. J. Med. 316, 1289–1294 (1987).
Swift, M. Morrell, D. Massey, R. & Chase, C. Incidence of cancer in 161 families affected by ataxia-telangiectasia. New Engl. J. Med. 325, 1831–1836 (1991).
Easton, D. Cancer risks in A-T heterozygotes. Int. J. Radiat Biol. 66, S177–182 (1994).
Gilad, S. et al. Predominance of null mutations in ataxia-telangiectasia. Hum. Mol. Genet. 5, 433–439 (1996).
Byrd, P. et al. Mutations revealed by sequencing the 5′ half of the gene for ataxia telangiectasia. Hum. Mol. Genet. 5, 145–149 (1996).
Telatar, M. et al. Ataxia-telangiectasia: mutations in ATM cDNA detected by protein-truncation screening. Am. J. Hum. Genet. 59, 40–44 (1996).
Wright, J. et al. A high frequency of distinct ATM gene mutations in ataxia-telangiectasia. Am. J. Hum. Genet. 59, 839–846 (1996).
Baumer, A. Bernthaler, U. Wolz, W. Hoehn, H. & Schindler, D. New mutations in the ataxia telangiectasia gene. Hum. Genet. 98, 246–249 (1996).
Wooster, R. et al. Absence of linkage to the ataxia-telangiectasia locus in familial breast cancer. Hum. Genet. 92, 91–94 (1993).
Vorechovsky, I. et al. The ATM gene and susceptibility to breast cancer: analysis of 38 breast tumors reveals no evidence for mutation. Cancer Res. 56, 2726–2732 (1996).
Vorechovsky, I. et al. ATM mutations in cancer families. Cancer Res. 56, 4130–4133 (1996).
FitzGerald, M. et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset of breast cancer. New Engl. J. Med. 334, 143–149 (1996).
Pippard, E.C. Hall, A.J. Barker, D.J.P. & Bridges, B.A. Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res. 48, 2929–2932 (1988).
Borresen, A.L. Anderson, T.I. Treti, S. Heiberg, A. & Muller, P. Breast cancer and other cancers in Norwegian families with ataxia-telangiectasia. Genes Chrom. Cancer 2, 339–340 (1990).
Athma, P. Rappaport, R. & Swift, M. Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet. Cytogenet. 92, 130–134 (1996).
Cunliffe, P.N. Mann, J.R. Cameron, A.H. Roberts, K.D. & Ward, H.W.C. Radiosensitivity in ataxia-telangiectasia. Br. J. Radiol. 48, 374–376 (1975).
Taylor, A.M.R. et al. Ataxia-telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258, 427–429 (1975).
Houldsworth, J. & Lavin, M. Effect of ionizing radiation on DNA synthesis in ataxia telangiectasia cells. Nucleic Acid Res. 8, 3709–3720 (1980).
Cole, J. et al. Comparative human cellular radiosensitivity. II The survival following gamma-irradiation of unstimulated (G°) T lymphocytes, T lymphocyte lines, lymphoblastoid cell lines and fibroblasts from normal donors, from ataxia-telangiectasia patients, and from ataxia-telangiectasia heterozygotes. Int. J. Radiat Biol. 54, 929–943 (1988).
Beamish, H. & Lavin, M. Radiosensitivity in ataxia-telangiectasia. Anomalies in radiation-induced cell cycle delay. Int. J. Radiat. Biol. 6, 175–184 (1994).
Thacker, J. Cellular radiosensitivity in ataxia-telangiectasia. Int. J. Radiat. Biol. 66, 587–596 (1994).
West, C. Elyan, S. Berry, P. Cowan, R. & Scott, D. A comparison of the radiosensitivity of lymphocytes from normal donors, cancer patients, individuals with ataxia-telangiectasia (A-T) and A-T heterozygotes. Int. J. Radiat. Biol. 68, 197–203 (1995).
Jorgensen, T.J. & Shiloh, Y. The ATM gene and the radiobiology of ataxia-telangiectasia. Int. J. Radiat. Biol. 69, 57–537 (1996).
Kastan, M. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587–597 (1992).
Khanna, K. & Lavin, M. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8, 3307–3312 (1993).
Xu, Y. & Baltimore, D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes Dev. 10, 2401–2410 (1996).
Savitsky, K. et al. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Hum. Mol. Genet. 4, 2025–2032 (1995).
Greenwell, P. et al. TEL1, a gene involved in controlling telomere length in S. cerevisiae, is homologous to the human ataxia telangiectasia gene. Cell 82, 823–829 (1995).
Morrow, D. Tagle, D. Shiloh, Y. Collins, F. & Hieter, P. TEL1, an S. cerevisiae homolog of the human gene mutated in ataxia telangiectasia, is functionally related to the yeast checkpoint gene MEC1. Cell 82, 831–840 (1995).
Paulovich, A. & Hartwell, L. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 82, 841–847 (1995).
Hartley, K. et al. DNA-dependent protein kinase catalytic subunit: a relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product. Cell 82, 849–856 (1995).
Hari, K. et al. The mei-41 gene of D. melanogaster is a structural and functional homolog of the human ataxia telangiectasia gene. Cell 82, 815–821 (1995).
Zakian, V. ATM-related genes; what do they tell us about functions of the human gene? Cell 82, 685–687 (1995).
Barlow, C. et al. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86, 159–171 (1996).
Xu, Y. et al. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10, 2411–2422 (1996).
Ramsay, J. Birrell, G. & Lavin, M. Breast cancer and radiotherapy in ataxia-telangiectasia heterozygote. Lancet 347, 1627 (1996).
Stine, G.J. Population genetics, in The new human genetics, (ed. Kevin Kane) 393–396 (Wm. C. Brown, Dubuque, Iowa, 1989).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
FitzGerald, M., Bean, J., Hegde, S. et al. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15, 307–310 (1997). https://doi.org/10.1038/ng0397-307
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng0397-307